 | • レポートコード：GIR-107A11926 • 出版社/出版日：GlobalInfoResearch / 2021年7月20日 • レポート形態：英文、PDF、83ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、全身性特発性若年性関節炎治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。全身性特発性若年性関節炎治療の種類別市場規模（アダリムマブバイオシミラー、カナキヌマブ、ゴリムマブ、トシリズマブバイオシミラー、その他）、用途別市場規模（クリニック、病院、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・全身性特発性若年性関節炎治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Alteogen Inc.、Bristol-Myers Squibb Company、Epirus Biopharmaceuticals, Inc.、Johnson & Johnson、Momenta Pharmaceuticals, Inc.、Mycenax Biotech Inc.、Novartis AG、Oncobiologics, Inc. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：アダリムマブバイオシミラー、カナキヌマブ、ゴリムマブ、トシリズマブバイオシミラー、その他 ・用途別分析2016年-2026年：クリニック、病院、その他 ・全身性特発性若年性関節炎治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・全身性特発性若年性関節炎治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・全身性特発性若年性関節炎治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・全身性特発性若年性関節炎治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・全身性特発性若年性関節炎治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Systemic Idiopathic Juvenile Arthritis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Systemic Idiopathic Juvenile Arthritis Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Systemic Idiopathic Juvenile Arthritis Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Systemic Idiopathic Juvenile Arthritis Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Adalimumab Biosimilar
Canakinumab
Golimumab
Tocilizumab Biosimilar
Others
Market segment by Application, can be divided into
Clinic
Hospital
Others
Market segment by players, this report covers
Alteogen Inc.
Bristol-Myers Squibb Company
Epirus Biopharmaceuticals, Inc.
Johnson & Johnson
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Novartis AG
Oncobiologics, Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Systemic Idiopathic Juvenile Arthritis Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Systemic Idiopathic Juvenile Arthritis Treatment, with revenue, gross margin and global market share of Systemic Idiopathic Juvenile Arthritis Treatment from 2019 to 2021.
Chapter 3, the Systemic Idiopathic Juvenile Arthritis Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Systemic Idiopathic Juvenile Arthritis Treatment market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Systemic Idiopathic Juvenile Arthritis Treatment research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Systemic Idiopathic Juvenile Arthritis Treatment
1.2 Classification of Systemic Idiopathic Juvenile Arthritis Treatment by Type
1.2.1 Overview: Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Type in 2020
1.2.3 Adalimumab Biosimilar
1.2.4 Canakinumab
1.2.5 Golimumab
1.2.6 Tocilizumab Biosimilar
1.2.7 Others
1.3 Global Systemic Idiopathic Juvenile Arthritis Treatment Market by Application
1.3.1 Overview: Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size & Forecast
1.5 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast by Region
1.5.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Region, (2016-2021)
1.5.3 North America Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Systemic Idiopathic Juvenile Arthritis Treatment Market Drivers
1.6.2 Systemic Idiopathic Juvenile Arthritis Treatment Market Restraints
1.6.3 Systemic Idiopathic Juvenile Arthritis Treatment Trends Analysis
2 Company Profiles
2.1 Alteogen Inc.
2.1.1 Alteogen Inc. Details
2.1.2 Alteogen Inc. Major Business
2.1.3 Alteogen Inc. Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
2.1.4 Alteogen Inc. Systemic Idiopathic Juvenile Arthritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Alteogen Inc. Recent Developments and Future Plans
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business
2.2.3 Bristol-Myers Squibb Company Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
2.2.4 Bristol-Myers Squibb Company Systemic Idiopathic Juvenile Arthritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.3 Epirus Biopharmaceuticals, Inc.
2.3.1 Epirus Biopharmaceuticals, Inc. Details
2.3.2 Epirus Biopharmaceuticals, Inc. Major Business
2.3.3 Epirus Biopharmaceuticals, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
2.3.4 Epirus Biopharmaceuticals, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Epirus Biopharmaceuticals, Inc. Recent Developments and Future Plans
2.4 Johnson & Johnson
2.4.1 Johnson & Johnson Details
2.4.2 Johnson & Johnson Major Business
2.4.3 Johnson & Johnson Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
2.4.4 Johnson & Johnson Systemic Idiopathic Juvenile Arthritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Johnson & Johnson Recent Developments and Future Plans
2.5 Momenta Pharmaceuticals, Inc.
2.5.1 Momenta Pharmaceuticals, Inc. Details
2.5.2 Momenta Pharmaceuticals, Inc. Major Business
2.5.3 Momenta Pharmaceuticals, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
2.5.4 Momenta Pharmaceuticals, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Momenta Pharmaceuticals, Inc. Recent Developments and Future Plans
2.6 Mycenax Biotech Inc.
2.6.1 Mycenax Biotech Inc. Details
2.6.2 Mycenax Biotech Inc. Major Business
2.6.3 Mycenax Biotech Inc. Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
2.6.4 Mycenax Biotech Inc. Systemic Idiopathic Juvenile Arthritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Mycenax Biotech Inc. Recent Developments and Future Plans
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
2.7.4 Novartis AG Systemic Idiopathic Juvenile Arthritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Novartis AG Recent Developments and Future Plans
2.8 Oncobiologics, Inc.
2.8.1 Oncobiologics, Inc. Details
2.8.2 Oncobiologics, Inc. Major Business
2.8.3 Oncobiologics, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
2.8.4 Oncobiologics, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Oncobiologics, Inc. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Systemic Idiopathic Juvenile Arthritis Treatment Players Market Share
3.2.2 Top 10 Systemic Idiopathic Juvenile Arthritis Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Systemic Idiopathic Juvenile Arthritis Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Application (2016-2021)
5.2 Systemic Idiopathic Juvenile Arthritis Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2016-2026)
6.2 North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2026)
6.3 North America Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Country
6.3.1 North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2016-2026)
6.3.2 United States Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2016-2026)
7.2 Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2026)
7.3 Europe Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Country
7.3.1 Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2016-2026)
7.3.2 Germany Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
7.3.3 France Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Region
8.3.1 Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Region (2016-2026)
8.3.2 China Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
8.3.5 India Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2016-2026)
9.2 South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2026)
9.3 South America Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Country
9.3.1 South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Systemic Idiopathic Juvenile Arthritis Treatment Market Size by Country
10.3.1 Middle East & Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Systemic Idiopathic Juvenile Arthritis Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Region (2021-2026)
Table 6. Alteogen Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Alteogen Inc. Major Business
Table 8. Alteogen Inc. Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
Table 9. Alteogen Inc. Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Company Major Business
Table 12. Bristol-Myers Squibb Company Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
Table 13. Bristol-Myers Squibb Company Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Epirus Biopharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 15. Epirus Biopharmaceuticals, Inc. Major Business
Table 16. Epirus Biopharmaceuticals, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
Table 17. Epirus Biopharmaceuticals, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 19. Johnson & Johnson Major Business
Table 20. Johnson & Johnson Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
Table 21. Johnson & Johnson Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Momenta Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 23. Momenta Pharmaceuticals, Inc. Major Business
Table 24. Momenta Pharmaceuticals, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
Table 25. Momenta Pharmaceuticals, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Mycenax Biotech Inc. Corporate Information, Head Office, and Major Competitors
Table 27. Mycenax Biotech Inc. Major Business
Table 28. Mycenax Biotech Inc. Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
Table 29. Mycenax Biotech Inc. Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 31. Novartis AG Major Business
Table 32. Novartis AG Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
Table 33. Novartis AG Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Oncobiologics, Inc. Corporate Information, Head Office, and Major Competitors
Table 35. Oncobiologics, Inc. Major Business
Table 36. Oncobiologics, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Product and Solutions
Table 37. Oncobiologics, Inc. Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million) by Players (2019-2021)
Table 39. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Share by Players (2019-2021)
Table 40. Breakdown of Systemic Idiopathic Juvenile Arthritis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Systemic Idiopathic Juvenile Arthritis Treatment Players Head Office, Products and Services Provided
Table 42. Systemic Idiopathic Juvenile Arthritis Treatment Mergers & Acquisitions in the Past Five Years
Table 43. Systemic Idiopathic Juvenile Arthritis Treatment New Entrants and Expansion Plans
Table 44. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million) by Type (2016-2021)
Table 45. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Share by Type (2016-2021)
Table 46. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Forecast by Type (2021-2026)
Table 47. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2021)
Table 48. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Forecast by Application (2021-2026)
Table 49. North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 50. North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 51. North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 52. North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 53. North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 54. North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 55. Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 56. Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 57. Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 58. Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 59. Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 60. Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 61. Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 62. Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 64. Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Region (2016-2021) & (USD Million)
Table 66. Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Region (2021-2026) & (USD Million)
Table 67. South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 68. South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 69. South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 70. South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 71. South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 72. South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 73. Middle East & Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 74. Middle East & Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 76. Middle East & Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 78. Middle East & Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Systemic Idiopathic Juvenile Arthritis Treatment Picture
Figure 2. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Type in 2020
Figure 3. Adalimumab Biosimilar
Figure 4. Canakinumab
Figure 5. Golimumab
Figure 6. Tocilizumab Biosimilar
Figure 7. Others
Figure 8. Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Application in 2020
Figure 9. Clinic Picture
Figure 10. Hospital Picture
Figure 11. Others Picture
Figure 12. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Region (2016-2026)
Figure 15. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Region in 2020
Figure 16. North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Systemic Idiopathic Juvenile Arthritis Treatment Market Drivers
Figure 22. Systemic Idiopathic Juvenile Arthritis Treatment Market Restraints
Figure 23. Systemic Idiopathic Juvenile Arthritis Treatment Market Trends
Figure 24. Alteogen Inc. Recent Developments and Future Plans
Figure 25. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 26. Epirus Biopharmaceuticals, Inc. Recent Developments and Future Plans
Figure 27. Johnson & Johnson Recent Developments and Future Plans
Figure 28. Momenta Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 29. Mycenax Biotech Inc. Recent Developments and Future Plans
Figure 30. Novartis AG Recent Developments and Future Plans
Figure 31. Oncobiologics, Inc. Recent Developments and Future Plans
Figure 32. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Share by Players in 2020
Figure 33. Systemic Idiopathic Juvenile Arthritis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share in 2020
Figure 35. Global Top 10 Players Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Share by Type in 2020
Figure 38. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share Forecast by Type (2021-2026)
Figure 39. Global Systemic Idiopathic Juvenile Arthritis Treatment Revenue Share by Application in 2020
Figure 40. Global Systemic Idiopathic Juvenile Arthritis Treatment Market Share Forecast by Application (2021-2026)
Figure 41. North America Systemic Idiopathic Juvenile Arthritis Treatment Sales Market Share by Type (2016-2026)
Figure 42. North America Systemic Idiopathic Juvenile Arthritis Treatment Sales Market Share by Application (2016-2026)
Figure 43. North America Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Country (2016-2026)
Figure 44. United States Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Systemic Idiopathic Juvenile Arthritis Treatment Sales Market Share by Type (2016-2026)
Figure 48. Europe Systemic Idiopathic Juvenile Arthritis Treatment Sales Market Share by Application (2016-2026)
Figure 49. Europe Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Country (2016-2026)
Figure 50. Germany Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Region (2016-2026)
Figure 58. China Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Systemic Idiopathic Juvenile Arthritis Treatment Sales Market Share by Type (2016-2026)
Figure 65. South America Systemic Idiopathic Juvenile Arthritis Treatment Sales Market Share by Application (2016-2026)
Figure 66. South America Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Systemic Idiopathic Juvenile Arthritis Treatment Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Systemic Idiopathic Juvenile Arthritis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source